Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™
PETALUMA, Calif. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of a new
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
PETALUMA, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has licensed its
View HTML
Toggle Summary Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
PETALUMA, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors.  Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s board with a track
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
Lead Researcher Mark Steven Nestor, M.D., Ph.D. Presented the Results of the Study at the Practical Symposium Dermatology Conference August 9-12, 2018 PETALUMA, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
Total Revenue up 20 % over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced financial results for the first quarter FY 2019
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call
PETALUMA, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced that financial results for its fiscal year 2019 first quarter, ended June 30, 2018 , will be released after the U.S. markets close on August 8, 2018 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results
Strong Annual Year-Over-Year Growth in Revenue of 30% $10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , June 13, 2018 (GLOBE NEWSWIRE) --   Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets
View HTML
Toggle Summary U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma’s Dermatology Products in Brazil
SAO PAULO, Brazil and PETALUMA, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- U.SK Dermatology, the dermatology arm of NC Group , which besides other businesses is the largest pharmaceutical organization in Brazil both in units sold and revenues, and Sonoma Pharmaceuticals, Inc.
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018 , will be released after the U.S. markets close on June 13, 2018 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
PETALUMA, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets unique and effective dermatological solutions, announced today that Marc Umscheid has been promoted to chief operating officer effective
View HTML